Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Medicines (Basel) · 2023 · PMC9861612 · PMID 36662497

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, we found a nonsignificant trend towards a reduced risk of all-cause mortality, ischemic S/SE and net clinical outcome between edoxaban 60 mg daily and warfarin.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.